Do You Know

03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *

Products » Items » Amoclan IV 1.2g°


Contraindicated
Risk of necrotizing enterocolitis in newborns

May be acceptable
Amoclan IV 1.2g° :
Type Medicine Withdrawn
Originator Augmentin IV 1.2g
Agent Hikma-Liban
Distributor Hikma-Liban
Laboratory Hikma Pharmaceuticals
Manufacturer Hikma Pharmaceuticals PLC
Manufacturing Type G
Origin Jordan
ATC J01CR02
Revision Date 01/12/2000

Your comment will appear shortly after approval

Amoclan IV 1.2g° :

Revision Date :


Effect Frequency
Acute generalised exanthematous pustulosis (AGEP) Very rare
Agranulocytosis Very rare
ALT increased Uncommon
Anaphylaxis Very rare
Angioedema (Angioneurotic oedema) (Quincke oedema) Very rare
AST increased Uncommon
Bleeding time prolonged Very rare
Cephalea Uncommon
Convulsion Very rare
Crystalluria Very rare
Dermatitis bullous Very rare
Dermatitis exfoliative Very rare
Diarrhoea (Diarrhea) Common
Erythema multiforme Rare
Haemolytic anemia Very rare
Hepatitis Very rare
Hypersensitivity vasculitis Very rare
Indigestion Uncommon
Injection site thrombophlebitis Rare
Interstitial nephritis Very rare
Jaundice cholestatic (Cholestatic icterus) Very rare
Leucopenia (Leukopenia) Rare
Lightheadedness Uncommon
Lyell Syndrome (Toxic epidermal necrolysis) Very rare
Mucocutaneous candidiasis Common
Nausea Uncommon
Neutropenia Rare
Prothrombin time prolonged Very rare
Pruritus Uncommon
Serum sickness Very rare
Skin Eruption Uncommon
Stevens-Johnson syndrome Very rare
Thrombocytopenia (Thrombopenia) Rare
Urticaria Uncommon
Vomiting Uncommon

Different Units By MoH Code

Revision Date : 01/12/2000

Amoclan IV 1.2g°  MoH 1108 :
Form Powder for solution for injection
Packaging Bottle
Package Size Box of 1
Strength 1.2g
Stratum N/A
NSSF ✘
Quarantine ✘
Reg. Number 973991/02
Submission date 01/01/2002
Registration Year 2002
Withdrawn Date 2016


Price Comparison

    ◼ Lebanon
    ◼ Country of Origin
    ◼ Reference Countries
    ◼ Other Countries
Prices are provided in Dollar ($)
You have to register to view this info

You have to register to view this info

You have to register to view this info